Dr. Markowski on phase 3 trial of sabizabulin (VERU-111) in mCRPC
Mark Christopher Markowski, MD, PhD, discusses a phase 3 trial exploring the novel oral cytoskeletal disruptor sabizabulin (VERU-111) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on at least 1 androgen receptor targeting agent. The study, which is currently recruiting (NCT04844749), was launched following positive phase 1b/2 data. Markowski, an assistant professor of Oncology at Johns Hopkins Medicine, was the lead study author on the phase 1b/2 study, data from which were shared at the 2021 ASCO Annual Meeting. (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056)
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
